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PCardiac Imaging in Heart Failure
Myocardial Iodine-123
Meta-Iodobenzylguanidine Imaging
and Cardiac Events in Heart Failure
Results of the Prospective ADMIRE-HF (AdreView
Myocardial Imaging for Risk Evaluation in Heart Failure) Study
Arnold F. Jacobson, MD, PHD,* Roxy Senior, MD,† Manuel D. Cerqueira, MD,‡
Nathan D. Wong, PHD,§ Gregory S. Thomas, MD, MPH,§ Victor A. Lopez, BS,§
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on behalf of the ADMIRE-HF Investigators
Princeton, New Jersey; London, United Kingdom; Cleveland, Ohio; Irvine, California; Caen, France;
Roseville, California; and Victoria, Texas
Objectives The ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study prospectively evaluated
iodine-123 meta-iodobenzylguanidine (123I-mIBG) imaging for identifying symptomatic heart failure (HF) patients
most likely to experience cardiac events.
Background Single-center studies have demonstrated the poorer prognosis of HF patients with reduced 123I-mIBG myocardial
uptake, but these observations have not been validated in large multicenter trials.
Methods A total of 961 subjects with New York Heart Association (NYHA) functional class II/III HF and left ventricular ejection
fraction (LVEF) 35% were studied. Subjects underwent 123I-mIBG myocardial imaging (sympathetic neuronal integ-
rity quantified as the heart/mediastinum uptake ratio [H/M] on 4-h delayed planar images) and myocardial perfusion
imaging and were then followed up for up to 2 years. Time to first occurrence of NYHA functional class progression,
potentially life-threatening arrhythmic event, or cardiac death was compared with H/M (either in relation to estimated
lower limit of normal [1.60] or as a continuous variable) using Cox proportional hazards regression. Multivariable anal-
yses using clinical, laboratory, and imaging data were also performed.
Results A total of 237 subjects (25%) experienced events (median follow-up 17 months). The hazard ratio for H/M 1.60
was 0.40 (p  0.001); the hazard ratio for continuous H/M was 0.22 (p  0.001). Two-year event rate was 15% for
H/M 1.60 and 37% for H/M 1.60; hazard ratios for individual event categories were as follows: HF progression,
0.49 (p  0.002); arrhythmic events, 0.37 (p  0.02); and cardiac death, 0.14 (p  0.006). Significant contributors
to the multivariable model were H/M, LVEF, B-type natriuretic peptide, and NYHA functional class. 123I-mIBG imaging
also provided additional discrimination in analyses of interactions between B-type natriuretic peptide, LVEF, and H/M.
Conclusions ADMIRE-HF provides prospective validation of the independent prognostic value of 123I-mIBG scintigraphy in assess-
ment of patients with HF. (Meta-Iodobenzylguanidine Scintigraphy Imaging in Patients With Heart Failure and Control
Subjects Without Cardiovascular Disease, NCT00126425; Meta-Iodobenzylguanidine [123I-mIBG] Scintigraphy Imag-
ing in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease, NCT00126438) (J Am Coll
Cardiol 2010;55:2212–21) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.01.014U
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May 18, 2010:2212–21 Myocardial 123I-mIBG Imaging in HFncreased myocardial sympathetic activity is a prominent fea-
ure of heart failure (HF) and is associated with progressive
yocardial remodeling, inexorable decline in left ventricular
unction, and worsening symptoms (1–3). Alterations in myo-
ardial sympathetic nerve activity also play an important role in
he generation of ventricular arrhythmias and sudden cardiac
eath (SCD) (4,5). Increased neuronal release of norepineph-
ine (NE) is usually accompanied by decreased neuronal NE
euptake due to post-transcriptional downregulation of the
ardiac NE transporter (6–8). The resultant increase in NE
oncentration in the sympathetic synaptic cleft induces desen-
itization of myocardial beta-adrenoceptors (9,10). Adrenore-
eptor inhibitors counter such alterations and improve survival
y retarding HF progression and preventing tachyarrhythmias
11,12). Accordingly, interrogation of myocardial sympathetic
ervous system activity has been suggested as an aid to
ssessment of prognosis and clinical management of HF
atients (13,14).
See page 2222
The decrease in the NE reuptake mechanism has been
uccessfully assessed by radionuclide imaging with the
odine-123–labeled NE analog meta-iodobenzylguanidine
123I-mIBG), which has demonstrated an excellent safety
rofile during more than 20 years of clinical use (5,13–15).
ptake of 123I-mIBG into myocardial sympathetic nerve
ndings is mediated by the NE transporter, and because the
ompound is not metabolized, the amount of 123I-mIBG
etention over several hours after administration is a reflection
f neuronal integrity (15). Reduced myocardial 123I-mIBG
ptake has been demonstrated to be an independent predictor
f adverse long-term outcome, and improvement in 123I-
IBG uptake is observed in response to effective HF therapy
13,16–21). Although there is extensive literature on 123I-
IBG imaging in both ischemic and nonischemic cardiomy-
pathy, most studies have been conducted at single centers
nvolving relatively small numbers of patients and have not
een performed under rigorous clinical trial conditions. As
uch, the potential usefulness of 123I-mIBG imaging in the
linical management of HF patients has remained uncertain.
The ADMIRE-HF (AdreView Myocardial Imaging for
isk Evaluation in Heart Failure) study consisted of 2
dentical open-label phase III studies to provide prospective
alidation of the prognostic role of quantitation of sympa-
hetic innervation of the myocardium using 123I-mIBG.
his paper presents the combined primary efficacy results
rom the 2 ADMIRE-HF studies.
ethods
tudy design. Ninety-six sites in North America (U.S. and
anada) and Europe participated in ADMIRE-HF. The
tudy was approved by the institutional review boards and
thics committees at each center, and all subjects signed
nformed consent before performance of any procedures. she first subject was imaged on
uly 27, 2005; the last subject was
maged on February 20, 2008.
The methods used in the trial
ave been described in detail
reviously (22). The primary in-
lusion criteria were HF (New
ork Heart Association [NYHA]
unctional class II or III) due to
schemic or nonischemic cardio-
yopathy; left ventricular ejec-
ion fraction (LVEF)35%; and
uidelines-based optimum phar-
acotherapy including beta-
locker, angiotensin-converting
nzyme inhibitor, and/or angio-
ensin receptor blocker (ARB).
ajor exclusion criteria were func-
ioning ventricular pacemaker; his-
ory of defibrillation to treat a pre-
ious ventricular arrhythmic event;
ardiac revascularization, implant-
ble cardioverter-defibrillator
ICD) implantation or acute myo-
ardial infarction within previous
0 days; and serum creatinine
3.0 mg/dl (265 mol/l) (22).
ithin 30 days before imaging, all subjects underwent a
omplete clinical evaluation, NYHA functional class assess-
ent, echocardiography, and blood draw for plasma B-type
atriuretic peptide (BNP) and NE levels. The echocardio-
raphic data and blood work were submitted to separate core
aboratories for analysis.
adionuclide imaging and analysis procedures. Imaging
rocedures are described in detail in the Online Appendix.
riefly, all subjects received 10 mCi (370 MBq; 10%) of
23I-mIBG (AdreView, GE Healthcare) and underwent an-
erior planar and single-photon emission computed tomogra-
hy (SPECT) imaging of the thorax beginning at 15 min
“early”) and 3 h 50 min (“late”) post-injection (Fig. 1). On a
eparate day, myocardial perfusion imaging (MPI) with
echnetium-99m (99mTc)-tetrofosmin (MyoView, GE
ealthcare) was performed as previously described (22). All
mages were processed by certified nuclear medicine technol-
gists and interpreted at an independent core laboratory (Icon
edical Imaging, Warrington, Pennsylvania). All planar and
PECT images were reviewed by 3 expert independent nuclear
ardiologists who were blinded to clinical data.
The heart/mediastinum ratio (H/M) was determined from
he counts/pixel in a visually drawn heart region of interest
ivided by the counts/pixel in a 77 pixel mediastinum region
f interest in the mid-line upper chest positioned to reflect the
ocation with lowest activity (i.e., nonspecific background).
ach reader validated the H/M determined for each planar
mage and scored all SPECT image sets employing a 17-
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
CE  cardiac event
HF  heart failure
H/M  heart/mediastinum
ratio
ICD  implantable
cardioverter-defibrillator
123I-mIBG  iodine-123
meta-iodobenzylguanidine
LVEF  left ventricular
ejection fraction
MPI  myocardial perfusion
imaging
NE  norepinephrine
NYHA  New York Heart
Association
SCD  sudden cardiac
death
SPECT  single-photon
emission computed
tomography
VT  ventricular
tachycardiaegment model and a scale of 0 to 4 (23).
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Myocardial 123I-mIBG Imaging in HF May 18, 2010:2212–21linical follow-up and event adjudication. All subjects
eceived standard clinical care and were followed up until:
) the subject completed a 2-year period after the 123I-
IBG study; 2) subject death was confirmed; 3) the subject
ithdrew from the study or was lost to follow-up; or 4) the
rial was terminated because the protocol-specified number
f cardiac events (CEs) had been confirmed. Complete
etails are provided in the Online Appendix.
The Clinical Adjudication Committee reviewed data from
ase report forms and source documents to confirm occurrence
f CEs, specifically: 1) HF progression: increase in symptom-
tic status from NYHA functional class II to III or IV, or
ncrease from NYHA class III to class IV; 2) potentially
ife-threatening arrhythmic event, including documented epi-
ode of spontaneous sustained (30 s) ventricular tachyar-
hythmia, resuscitated cardiac arrest, or appropriate ICD dis-
harge (antitachycardia pacing or defibrillation); or 3) cardiac
eath (further classified as due to HF progression, sudden
ardiac death [SCD], or other causes).
tatistical analysis. Statistical analyses were performed at
he University of California, Irvine (by V.A.L. and N.D.W.).
he univariate primary and secondary analyses were performed
n the pooled ADMIRE-HF dataset using consensus H/M
esults for each subject. The pre-specified primary end point
as the late H/M in relation to time-to-occurrence of the first
E in trial subjects. This single 123I-mIBG value was selected
or the primary analysis because of the extensive literature
upporting its prognostic significance (24,25). Complete 123I-
IBG and MPI SPECT data were collected for exploratory
valuations, and these data were included in preplanned
econdary analyses for each of the 2 trials. Complete details
f statistical analyses are provided in the Online Appendix.
The primary analysis was based on subjects classified into 2
re-specified groups, late H/M 1.6 and 1.6 (22). The
nalysis employed a univariate Cox proportional hazards model
tted to the time to first occurrence of a CE (composite of 3
E categories) (26). Secondary Cox proportional hazards
nalyses were performed using the continuous numerical H/M
ather than the binary division. Additional Cox proportional
azards analyses were performed for each of the 3 event
ategories, providing estimates of the hazard ratios for occur-
ence of each event category independent of the others (e.g.,
omparing subjects who had an HF progression CE vs. those
ho did not). Only the time to occurrence of the first event in
category for a given subject was used. Kaplan-Meier survival
nalyses were also performed on the primary and secondary
nd point data.
All multivariable analyses employed Cox proportional haz-
rds methods with backwards elimination. For each phase III
tudy, separate multivariable analyses were performed using the
PECT interpretations for each blinded reader. Additional
ultivariable analyses were performed on the pooled
DMIRE-HF data using only the planar (early and late)
23I-mIBG results; clinical variables such as age, sex, serum
reatinine, systolic blood pressure; and cardiac risk factors suchPRE-IMAGING ASSESSMENTS 
• Clinical evaluation
• NYHA HF classification 
• Blood for NE and BNP
• Echocardiography for LV volumes and 
myocardial mass
DOSING
• Administration of 123I-mIBG
POSTADMINISTRATION
(15 minutes)
• Anterior planar image of the thorax
(25 minutes)
• SPECT imaging
(3 hours 50 minutes)
• Anterior planar image of the thorax
(4 hours)
• SPECT imaging
CLINICAL FOLLOW-UP
3-Month Intervals and End of Study
• Limited physical exam
• Vital signs, O2 saturation
• Concomitant medications
• NYHA HF classification
• Recording of the occurrence of cardiac 
events
• Recording of hospitalizations, changes in 
clinical condition,  performance of cardiac 
procedures, ICD interrogations, death
SEPARATE DAY
• Administration of 99mTc-tetrofosmin
• SPECT imaging
EVENT ADJUDICATION
• Determination by Clinical Adjudication 
Committee (CAC)
• Specification of event category
Figure 1 The ADMIRE-HF Study Scheme
Flow diagram of the ADMIRE-HF (AdreView Myocardial Imaging for Risk Eval-
uation in Heart Failure) study procedures, including pre-iodine-123 meta-
iodobenzylguanidine (123I-mIBG) clinical assessments, 123I-mIBG and
technetium-99m (99mTc)-tetrofosmin imaging studies, and in-person assess-
ments at 3-month intervals for 2 years. BNP  B-type natriuretic peptide; HF 
heart failure; ICD  implantable cardioverter-defibrillator; LV  left ventricular;
NE  norepinephrine; NYHA  New York Heart Association; SPECT  single-
photon emission computed tomography.s hypertension, dyslipidemia, and diabetes. In the protocol-
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May 18, 2010:2212–21 Myocardial 123I-mIBG Imaging in HFpecified multivariable analyses, myocardial washout was not
ncluded because it is derived from the same data used in
alculating early and late H/M. However, as the prognostic
ignificance of washout is widely cited in the literature (24,25),
dditional analyses examining the impact of this variable were
erformed.
Statistical significance for the univariate Cox proportional
azards analyses of the composite primary end point was set
t p  0.025 (alpha  0.05 split between the analyses using
/M divided at 1.60 and as a continuous variable). All other
nalyses used a significance level of p  0.05.
esults
tudy participants. 123I-mIBG studies were performed in
85 subjects (453 and 532 subjects in the 2 phase III trials).
f these 985 subjects, 21 subjects were withdrawn because
f protocol violations (only discovered post-dosing; n 17),
linical Characteristics of the Heart Failure SubjectsTable 1 Clinical Characteristics of the Heart Failure Subjects
n 961
Sex, male (%) 80.1
Race, white (%) 74.9
Body mass index (kg/m2) 29.2 6.1
ACE inhibitors/ARBs (%) 94.2
Beta-blockers (%) 91.9
Lipid-lowering agents (%) 74.6
Aldosterone antagonist (%) 38.9
Diabetes (%) 36.0
Hypertension (%) 64.5
Smoker, current or past (%) 73.9
Dyslipidemia (%) 72.4
Heart failure: NYHA functional class II, III (%) 82.7, 17.3
Heart failure: ischemic, nonischemic (%) 66.0, 34.0
LVEF (%) 27.1 6.1
CE-I  angiotensin-converting enzyme inhibitor; ADMIRE-HF  AdreView Myocardial Imaging for
isk Evaluation in Heart Failure; ARB  angiotensin receptor blocker; LVEF  left ventricular
jection fraction; NYHA  New York Heart Association.
Comparison of Characteristics of Subjects WithTable 2 Comparison of Characteristics of Su
Characteristic
Subjects W
(n 
Male sex (%)
Age (yrs) 61.5
LVEF (%) 25.0
ACE-I or ARB (%)
Beta-blocker (%)
Aldosterone antagonist (%)
HF class: NYHA II, III (%) 75.1
HF etiology: ischemic, nonischemic (%) 60.3
BNP (ng/l) (n  926) 393.1
Plasma NE (pg/ml) (n  913) 721.9
Early H/M 1.53
Late H/M 1.39
Washout (%) 41.8
BNP  B-type natriuretic peptide; HF  heart failure; H/M  hea
counts/pixel (cpi) early mediastinum (M) cpi] [late H cpi* late M cpi*])
in Table 1.dverse events (n  3; nausea; hypoglycemia secondary to
nsulin administration; acute myocardial infarction in sub-
ect with ischemic electrocardiography changes before 123I-
IBG dosing), or subject request on the day of dosing (n 
). In addition, images from 2 subjects were not submitted
or central reading, and planar images from 1 subject were
onsidered nondiagnostic by the readers. Therefore, the
valuable efficacy population consisted of 961 subjects. The
emographic information for those subjects is summarized
n Table 1.
During the follow-up period of 2 days to 30.4 months
median 17 months), 237 first CEs were observed: HF
rogression in 163 subjects, arrhythmic events in 50 sub-
ects, and cardiac death in 24 subjects. Fifty-two subjects
ad CEs in more than 1 category during follow-up, result-
ng in the following subject totals in each CE category: HF
rogression, n  176; arrhythmic events, n  64; cardiac
eath, n  53. The total number of deaths during the trial
as 81 (8%; 28 noncardiac). Characteristics of subjects
ased on occurrence of CEs are compared in Table 2. There
as no difference in the age, sex, and medication usage of
ubjects who did and did not experience CEs. Subjects who
xperienced events were more likely to have NYHA func-
ional class III symptoms, HF of nonischemic etiology,
ower LVEF, and higher levels of BNP and NE.
The mean late H/M was 1.44 (standard deviation 0.20),
nd the distribution of this parameter was symmetric (first,
econd, and third quartiles of 1.30, 1.42, and 1.57, respec-
ively). A total of 201 subjects (21%) had H/M 1.60
protocol-defined binary division) (22).
rimary analyses. The CE risk (primary end point) was
ignificantly lower for subjects with H/M 1.60, with
azard ratio of 0.40 (97.5% CI: 0.25 to 0.64; p  0.001).
urvival analysis showed 2-year event rates of 38% versus
5% for the 2 H/M groups (Fig. 2). The Cox proportional
azards analysis based on the continuous numerical H/M
Without Cardiac Eventsts With and Without Cardiac Events
ents Subjects Without Events
(n  724) p Value
79.0 0.129
62.7 11.3 0.243
27.8 5.8 0.001
94.5 0.484
92.0 0.834
37.4 0.095
85.2, 14.8 0.001
67.8, 32.2 0.035
.9 217.1 339.2 0.001
.1 641.7 344.6 0.003
1.58 0.20 0.003
1.46 0.21 0.001
36.1 17.2 0.001
iastinum ratio; NE  norepinephrine; Washout  ([early heart (H)andbjec
ith Ev
237)
83.5
13.5
6.6
93.3
91.6
43.5
, 24.9
, 39.7
472
408
0.19
0.18
17.3
rt/med
/(early H cpi early M cpi) (*decay-corrected); other abbreviations as
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Myocardial 123I-mIBG Imaging in HF May 18, 2010:2212–21emonstrated an even lower hazard ratio (0.22; 97.5% CI:
.10 to 0.47; p 0.001). The analyses based on the individual
vent categories showed significant differences for all 3, with
he lowest hazard ratio for subjects with high H/M being for
ardiac death (0.14; 95% CI: 0.03 to 0.58; p  0.006) (Fig. 2,
able 3).
Additional analyses considering cardiac death and
ll-cause mortality are presented in Figures 2 and 3 and
able 4. For H/M 1.60, 2-year probabilities of cardiac
eath and all-cause mortality were 11.2% and 16.1%
A
C
E
Figure 2 Cumulative Event Curves Comparing Subjects With H/
(A) Composite primary end point; (B) heart failure progression; (C) arrhythmic eve
For each analysis, the former group has a significantly higher event rate. H/M  hersus 1.8% and 3.0% for the group with H/M 1.60. breated as a continuous variable, there was a progressive
ecline in both cardiac and all-cause mortality from
20% for H/M 1.10 to 0% for H/M 1.80. The
-year cardiac death rate in the total population was
.1%, compared with the rate in the first decile (H/M
1.20; n  92) of 19.1%.
econdary analyses. The multivariable analyses from the
ndividual phase III studies demonstrated a consistently
ignificant contribution for the late H/M across blinded
eaders. These same analyses showed no consistent contri-
1.60 Versus >1.60
) cardiac death; (E) all-cause mortality.
ediastinum ratio.B
D
M <
nt; (D
eart/mution to event prediction for the 123I-mIBG and 99mTc-
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May 18, 2010:2212–21 Myocardial 123I-mIBG Imaging in HFetrofosmin SPECT results. The multivariable analysis of
he pooled ADMIRE-HF data using only the planar
23I-mIBG imaging results produced a model with 4 inde-
endent variables contributing to the prediction of the
rimary outcome events: late H/M, LVEF, NYHA func-
ional class, and plasma BNP (Table 5). In univariate Cox
roportional hazards analyses, the early and late H/M and
ashout all were significantly associated with risk of CEs. In
ultivariable analyses with these 3 parameters, the late
Results of Cox Proportional Hazards Model forH/M Thresh ld of 1.60 on Cardi c Events CategTable 3 Results of Cox Proportional Haz dsH/M Threshold of 1.60 on Cardiac
Event Category N
Heart failure progression 961
Potentially life-threatening arrhythmia 961
Cardiac death 961
CI  confidence interval; H/M  heart/mediastinum ratio.
A
B
Figure 3 2-Year Cardiac Death and
All-Cause Mortality Rates Versus H/M
Two-year cardiac death (A) and all-cause mortality (B) rates show progressive
decline from 20% for heart/mediastinum ratio (H/M) 1.10 to 0% for H/M
1.80.H/M was consistently the only parameter that retained
tatistical significance.
omparison with other prognostic markers. The utility
f addition of the H/M to 2 frequently used markers of
rognosis in HF patients, BNP and LVEF, was examined
n subanalyses. The median BNP level in the 926 subjects
ith adequate blood samples was 140 ng/l, and there was a
mall but statistically significant negative correlation be-
ween plasma BNP and H/M (Online Fig. 1). There were
ighly significant differences in the total CE and cardiac
eath rates between subjects with BNP levels below and
bove the population median (Figs. 4A and 4B). Addition
f the binary H/M result provided further stratification for
otal CEs and cardiac death in the high-risk BNP popula-
ion and a difference of borderline significance for total CEs
n subjects with BNP 140 ng/l (Figs. 4C and 4D). The
-year CE rate for subjects with BNP 140 ng/l was 42%,
ut among the subset with H/M1.60, the rate was 20.5%.
here were no cardiac deaths among the 57 subjects with
NP 140 ng/l and 123I-mIBG H/M 1.60, compared
ith 42 cardiac deaths among the 406 subjects (10.3%) with
bove-median BNP and H/M 1.60.
Median LVEF in the 961 subjects was 29%, and there
as a modest but statistically significant positive correlation
etween LVEF and H/M (Online Fig. 2). There were
ighly significant differences in total event and cardiac death
ates between subjects with LVEF levels below and above
he population median (Figs. 4E and 4F). Addition of the
inary H/M result provided further stratification for HF
ubjects in both LVEF groups (Figs. 4G and 4H). The
-year CE rate for subjects with LVEF 30% and H/M
1.60 was less than half that of all subjects with LVEF
30% (17.6% vs. 40.3%). There were 2 cardiac deaths
mong the 81 subjects (2.5%) with LVEF 30% and H/M
1.60 as compared with 39 cardiac deaths among the 409
9.5%) with LVEF 30% and H/M 1.60. There were no
el for
s Categories
l Events
% Hazard Ratio (95% CI) p Value
18.3 0.49 (0.32–0.77) 0.002
6.7 0.37 (0.16–0.85) 0.020
5.5 0.14 (0.03–0.58) 0.006
roportions of Subjects With Cardiac andll-Cause Death in Relation o H/M Threshold of 1.60Table 4 Proportion f Subjects With Cardiac andAll-Cause Death in Relation to H/M Threshold of 1.60
H/M N
Cardiac
Deaths All Deaths
n % n % p Value
1.60 760 51 6.7 77 10.1 0.002
1.60 201 2 1.0 4 2.0 0.002oriesMod
Event
Tota
n
176
64
53/M  heart/mediastinum ratio.
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Myocardial 123I-mIBG Imaging in HF May 18, 2010:2212–21ardiac deaths among the 120 subjects with LVEF 30%
nd H/M 1.60.
Further analyses examined the interaction of H/M,
VEF, and BNP in the 926 subjects with BNP results.
mong the 273 subjects with above-median values for BNP
nd below-median LVEF values, there were significantly
ower 2-year primary event and cardiac death rates for subjects
ith H/M 1.60 compared with H/M 1.60 (Fig. 5A).
onsidering values of all 3 parameters in the most abnormal
uartile (H/M 1.30, LVEF 23%, BNP 311.4 ng/l),
he highest and lowest rates of primary events and cardiac
eaths were among the 38 and 456 subjects with all 3
arameters or none in the most abnormal quartile, respec-
ively (Figs. 5B and 5C).
Among the 10% of subjects with the lowest LVEF
20%; n  98), H/M values still discriminated between
igher- and lower-risk subpopulations. Thirty-five of 61
ubjects (57%) with H/M 1.40 had outcome events,
ompared with 10 of 37 (27%) with H/M 1.40 (p 
.004). Considering this low LVEF decile in conjunction
ith subjects in the highest-risk deciles for H/M (1.20)
nd BNP (595.9 ng/l), 31 cardiac deaths (58% of the
tudy total) occurred among the 233 subjects (24%) with at
east 1 such high-risk value (p  0.001 compared with 22
ardiac deaths among the remainder of the population [n 
27]). Each of the 3 parameters alone identified a subset of
he subjects who experienced cardiac death (BNP, n 18;
/M, n  13; LVEF, n  13).
rrhythmic events. A total of 86 subjects (9%) experi-
nced either nonfatal arrhythmic events (self-limited ven-
ricular tachycardia [VT], n  12; resuscitated cardiac
rrest, n  6; appropriate ICD discharges, n  45) or SCD
n  23). These combined “arrhythmic” events were signif-
cantly more common in subjects with H/M 1.60 (79 of
60 [10.4%] vs. 7 of 201 [3.5%]; p  0.01). The highest
revalence of arrhythmic events was in the H/M range 1.30
o 1.39 (27 of 206; 13.1%). The highest H/M in a subject
ho experienced a fatal arrhythmic event was 1.60. Only 5
rrhythmic events occurred in the 191 subjects with H/M
1.60 (2.6%); 2 of 137 subjects with no ICD experienced
elf-limited episodes of VT, whereas 3 of 54 subjects with
CDs had device activations (2 antitachycardia pacing, 1
esults of Multivariable Cox Proportionalazard Analysis of Time to Cardiac EventsTable 5 Results of Multiva iable Cox ProportionalHazards Analysis of Time to Cardiac Events
Variable Hazard Ratio (95% CI) p Value
H/M 0.36 (0.17–0.75) 0.006
LVEF 0.95 (0.93–0.97) 0.001
NYHA functional class 1.48 (1.08–2.02) 0.015
BNP 1.00 (1.00–1.00)* 0.001
 903 subjects with complete data; 224 cardiac events. *Value represents incremental hazard
or 1 unit change (1 ng/l) and is rounded from 1.0004 (1.0002 to 1.0007).
BNP  B-type natriuretic peptide; H/M  heart/mediastinum ratio; LVEF  left ventricular
jection fraction; NYHA  New York Heart Association; CI  confidence interval.irect current shock). Siscussion
23I-mIBG has been in clinical use in Japan and Europe for
decades, and a large number of published reports have
ocumented abnormalities of myocardial sympathetic in-
ervation in various cardiovascular diseases (13,14,16–21,
4,25). A recent meta-analysis of 18 studies and 1,755
atients confirmed that HF patients with reduced late H/M
r increased 123I-mIBG washout rate have a worse progno-
is as compared with patients with normal 123I-mIBG
ptake and washout parameters (24). In addition to predic-
ion of HF progression and death, abnormal 123I-mIBG
ptake and washout have also been shown to be associated
ith increased incidence of SCD and appropriate ICD
ischarges (27,28). These reports have supported the use-
ulness of 123I-mIBG imaging for predicting potentially
atal outcomes in HF patients over follow-up periods of
onths to years. ADMIRE-HF provides the first large,
rospective confirmation of the strong prognostic value of
uantitation of cardiac adrenergic neuronal activity in HF
atients. The current results also suggest a potential bene-
cial application for the 123I-mIBG imaging procedure for
dentifying HF patients at very low and very high risks for
ear-term morbidity and mortality.
ole of neurohormonal regulation in HF. Observations
hat patients with HF have increased circulating cat-
cholamines and downregulation of beta-adrenergic recep-
ors (6–10) have focused particular attention on the poten-
ial for molecular imaging of in vivo myocardial NE kinetics
o provide improved risk stratification for the HF patient
opulation (24,25). Direct examination of cardiac neuronal
tatus may be more informative than assessment of systemic
drenergic activity in that the 123I-mIBG H/M uptake ratio
as a significant contributor to the ADMIRE-HF multi-
ariable risk model, but plasma NE was not.
Preserved neuronal uptake of 123I-mIBG identified a very
ow-risk HF population, with late H/M1.60 (21% of trial
ubjects) associated with 1%/year incidence of cardiac
eath. In contrast, among the 10% of subjects with H/M
1.20, annual rate of cardiac mortality (9.6%) was 10-fold
reater. The results of the 123I-mIBG imaging procedure
ould therefore potentially identify approximately one-third
f the HF population studied as either at substantial risk for
ear-term mortality or to be at low risk on the current level
f therapy.
linical implications of ADMIRE-HF. ADMIRE-HF
id not directly evaluate the potential benefit of 123I-mIBG
maging as an aid to clinical management of HF patients,
ut the study suggests that in appropriately selected pa-
ients, this imaging procedure could alert clinicians to the
otential need for considering additional treatments. For
xample, there were 74 ADMIRE-HF subjects who were
50 years old and had BNP 100 ng/l. Forty-seven of
hese subjects had H/M 1.60, of whom 13 developed CE,
ncluding 3 ICD activations, 1 episode of sustained VT, and 1
CD. Nine of these subjects had HF progression (including 1
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Figure 4 Cumulative Event Curves in Relation to BNP, LVEF, and H/M
There is a highly significant difference in primary event (A) and cardiac death rates (B) between subjects with B-type natriuretic peptide (BNP) below and above the
median value of 140 ng/l. Addition of the heart/mediastinum ratio (H/M) (1.60 vs. 1.60) further stratifies subjects with high BNP (C, D). There is a highly significant
difference in primary event (E) and cardiac death rates (F) between subjects divided at the median left ventricular ejection fraction (LVEF) of 29%. Addition of the H/M
(1.60 vs. 1.60) further stratifies subjects in both LVEF groups (G, H).
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Myocardial 123I-mIBG Imaging in HF May 18, 2010:2212–21ho had previously experienced an ICD shock). Twenty-seven
f these 47 subjects did not have ICDs, including the subject
ho died suddenly. Knowledge of the higher risk associated
ith abnormal cardiac innervation might have facilitated con-
ideration of more aggressive treatment (such as earlier use of
esynchronization therapy) in these subjects.
As a marker of adverse prognosis and cardiac death, BNP
ad the strongest predictive power (highest chi-square
alue) in the multivariable analyses. However, as demon-
trated in those analyses and in the analyses restricted to
/M, BNP, and LVEF, the H/M provided significant
nformation to complement BNP for identifying subjects at
he highest risk for CEs and cardiac death. H/M also
tratified risk among subjects with the lowest LVEF values
20%), including identifying a small low-risk cohort with
/M 1.60 (12 of 98; 12%). The likelihood of cardiac
eath was more than 4 times greater in the subpopulation of
ubjects with extreme deciles for at least 1 of the 3
arameters of BNP, H/M, and LVEF compared with the
emainder of the trial population (13.4% vs. 3.0%).
tudy limitations. Failure of the 123I-mIBG and 99mTc-
etrofosmin SPECT results to contribute to the multivariable
isk models may have been a direct consequence of the rigorous
esign of the phase III clinical trials. The readers scored all
23I-mIBG SPECT exams without reference to either the
lanar images (and the calculated H/Ms) or the 99mTc-
etrofosmin SPECT studies. The blinded mixture of ischemic
nd nonischemic cardiomyopathy subjects also made it more
hallenging for the readers to assign defect severity to the
yocardial segments based on global versus regional reduction
n 123I-mIBG uptake. Determination of the potential value of
PI SPECT, included in this study to assess whether quan-
itation of innervation/perfusion mismatch would augment
rediction of arrhythmic CEs (10,19), was also affected by the
nconsistency in the visual 123I-mIBG SPECT assessments.
he planar H/M succeeded because it was a reproducible
uantitative result; it is likely that similar success with SPECT
ill require use of automated quantitative analysis procedures.
As the present study involved only a single 123I-mIBG
maging procedure, short-term reproducibility of the H/M
eterminations was not assessed. Most published studies
hat included replicate 123I-mIBG exams were examining
he effect of medications or devices and involved inter-scan
ntervals of 6 to 12 months (20,21). However, even modest
ntra-subject variability in the H/M measurements would be
nlikely to change the highly significant results obtained in
his study, particularly for individuals with either severely
bnormal or normal cardiac uptake.
onclusions
he ADMIRE-HF demonstrated the capacity of quantita-
ion of sympathetic innervation of the myocardium, mea-
ured by the H/M on 123I-mIBG scintigraphy, for predict-
ng prognosis for significant cardiac events in subjects withB
A
C
Figure 5
2-Year Primary Event and Cardiac
Death Rates and Cumulative Event
Curves in Relation to BNP, LVEF, and H/M Values
(A) Among the 273 subjects with both BNP 140 ng/l and LVEF 30%, event
rates are significantly lower among subjects with H/M 1.60. Highest event
rates are in subjects with H/M 1.20. (B, C) In relation to the most abnormal
quartiles of BNP (31 ng/l), LVEF (23%), and H/M (1.30), there is a highly
significant difference in primary event rates (B) between subjects with 0, 1, 2,
and 3 of these high-risk values. Although the same progression is seen for car-
diac death (C), the differences between the N  0 and N  1 curves and the
N  2 and N  3 curves do not reach statistical significance. Abbreviations as
in Figure 4.F and significant left ventricular dysfunction. This is the
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May 18, 2010:2212–21 Myocardial 123I-mIBG Imaging in HFopulation to which guidelines for use of implanted devices
or management of HF and arrhythmic event risk usually
pply (29). ADMIRE-HF showed a highly significant
elationship between time to HF-related events and the
/M, which was independent of other commonly measured
arameters such as LVEF and BNP, as well as demographic
arameters such as age and renal function, in an HF
opulation on guidelines-based contemporary therapy. The
tudy also showed a clear association between severity of
yocardial sympathetic neuronal dysfunction and risk for
ubsequent cardiac death.
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